Physician profile
Michael Mitchell
NPI 1215988357
$1,813.31
in general payments reported to CMS, 2019-2025
21 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.55 · 2021: $14.72 · 2022: $29.19 · 2024: $678 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $352.37 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $270.93 | 2024-2025 | Caplyta |
| Almatica Pharma LLC | $188.23 | 2024-2025 | Loreev Xr |
| Lundbeck LLC | $157.35 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $149.98 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $112.85 | 2024-2025 | Austedo Xr, Austedo Xr |
| Tempus Ai, INC | $97.08 | 2024 | |
| Vanda Pharmaceuticals INC. | $95.66 | 2024-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $57.36 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $47.01 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $44.86 | 2025 | Lybalvi |
| Axsome Therapeutics, INC. | $39.08 | 2025 | Auvelity |
| Bausch Health US, LLC | $37.35 | 2025 | Wellbutrin, Aplenzin |
| Sunovion Pharmaceuticals INC. | $29.19 | 2022 | |
| Greenwich Biosciences, INC. | $26.55 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.49 | 2025 | |
| Ironshore Pharmaceuticals INC. | $19.45 | 2024 | |
| Neos Therapeutics, Lp | $18.60 | 2025 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $16.52 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $15.68 | 2024 | Spravato |
| Eisai INC. | $14.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.